Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide – a drug known as Zepbound™ – on weight ...

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1, receptor agonist, has shown promise in promoting weight loss and improving ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone ... versus monlunabant Nimacimab Phase 2a CBeyond™ top-line randomized data expected late Q3/early Q4 2025 SAN ...

Even more encouragingly, most people maintained the weight loss for the entire three-year study. “Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or obesity who do not have diabetes, according to ...

The Food and Drug Administration (FDA) does not regulate the safety, effectiveness, or quality of compounded tirzepatide. Some doctors also prescribe Mounjaro off-label for weight loss.

It's a drug called tirzepatide ... an average of 20% of their body weight. Now researchers want to know if it helps with sleep apnea because of the weight loss, or does it change brain function ...

However, the drug did not decrease the slowing down of their metabolic rate usually observed with weight loss. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, or GIP, and ...

Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone. “This new preclinical study highlights that a truly peripherally-restricted CB1 inhibitor ...